Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer.
Breast., Oct;20 Suppl 3:S150-2 (2011)
Impact of multigene assays in early stage breast cancer.
Oncologist., 16(11):1482-3 (2011)
Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Anticancer Res., Oct;30(10):3853-67 (2010)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Lancet., Aug;374(9687):379-86 (2009)
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Breast., Oct;18 Suppl 3:S141-5 (2009)
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
J. Clin. Oncol., Apr;28(10):1671-6 (2010)
Reducing the global breast cancer burden: the importance of patterns of care research.
Clin. Breast Cancer., Dec;6(5):412-20 (2005)
Correlation of nipple aspiration and ductal lavage cytology with histopathologic findings for patients before scheduled breast biopsy examination.
Am. J. Surg., Jan;191(1):57-60 (2006)
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
Clin Lung Cancer., May;7(6):417-9 (2006)
Clinical factors used to support prophylactic mastectomy for a male BRCA2 mutation carrier.
Surgery., May;139(5):704-6 (2006)
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
J. Clin. Oncol., Aug;26(24):3950-7 (2008)
Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
J. Clin. Oncol., Nov;26(33):5380-5 (2008)
Multimodality therapy for stage III non-small-cell lung cancer.
J. Clin. Oncol., May;23(14):3257-69 (2005)
Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer.
Curr Oncol Rep., Jan;2(1):54-63 (2000)
Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. A review, with a focus on recent trimodality trials.
Chest., Jan;103(1 Suppl):43S-50S (1993)
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Breast Cancer Res. Treat., 22(3):273-84 (1992)
Adjuvant chemotherapy and endocrine therapy for node-positive and node-negative breast carcinoma.
Clin Obstet Gynecol., Dec;32(4):835-57 (1989)
Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Cancer Chemother. Pharmacol., 27(1):33-40 (1990)
Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma.
Cancer Treat. Res., 105:149-70 (2001)
1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Cancer Res., Mar;49(6):1383-9 (1989)